The launch of Buprenorphine gives Arrow first to market success once again!
Arrow Generics has once again beaten the competition to be first to market with the launch of Arrow’s generic version of Buprenorphine sublingual tablets. The launch of this important molecule continues to demonstrate a commitment to bring technically difficult products to market at the earliest date possible. The product is now available in 3 strengths, 0.4mg, 2mg and 8mg, all in blister packs of 7 and can be sourced from UK wholesalers from Monday 3rd November 2008
This further adds to Arrow Generics’ growing reputation for first to market successes. Other launches of this nature include budesonide nebulisation solution, doxazozin 4mg xl, felodipine, mirtazapine 15 and 45mg tablets, paracetamol capsules 500mg in POM 100 packs and terbutaline nebulisation solution.
For further information please contact us via the web page.
Published 2008-10-31 07:30:00
